US · Healthcare · Medical Devices
EPS came in at 0.56 against a street estimate of 0.48 — a beat of 16.7%.
Analysts rate Integra LifeSciences Holdings a hold (3 buy, 5 hold, 4 sell out of 12) with an average price target of $19.56.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.27% |
| Rubric Capital Management LP | 9.97% |
| Vanguard Portfolio Management, LLC | 4.74% |
| Morgan Stanley - Brokerage Accounts | 4.61% |
| Fuller & Thaler Asset Management Inc | 4.54% |
| Amvescap Plc. | 4.48% |
| Paradigm Capital Management, Inc. | 4.42% |
| Vanguard Capital Management, LLC | 3.72% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or earnings data are | 2026-09-08 |
| Quarterly report · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORP - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $810.7 million (2026) vs. $798.3 million (202 | 2026-07-29 |
| Results announced · Q3 2026 INTEGRA LIFESCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $418.8 million, up 0.8% reported / 0.7% organic vs. prior year • | 2026-07-29 |
| Board / officer change · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 7, 2026 • 3,550,000 additional shares approv | 2026-05-08 |
| Quarterly report · Q1 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $391.9 million (vs. $382.7 million in Q1 | 2026-05-05 |
| Board / officer change · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Dr. Stuart Essig appointed President and Chief Executive Officer eff | 2026-05-05 |
| Proxy statement · Q4 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – 2026 PROXY SUMMARY CEO COMPENSATION • Mojdeh Poul (President and CEO) – Total compensation figure not pr | 2026-04-06 |
| Annual report FY2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – 2025 10-K SUMMARY HEADLINE NUMBERS • Company is a global medical technology manufacturer with 77.9 milli | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Integra LifeSciences Holdings — free to start.
Google PlayApp StoreData updated 2026-09-18.